Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections

References

• De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev Med. Viral 5,149–164 (1995).
   Web of Science ®Google Scholar
• Field AK, Biron KIK. 'The end ofinnocence' revisited: resistance ofherpesviruses to antiviral drugs. Gun. Mcrobiol Rev 7, 1–13 (1994).
   PubMed Web of Science ®Google Scholar
• De Clercq E. Broad spectrum antiDNAvirus and antiretrovirus activity of phosphonylmethoxyalkylpurines and pyrimidines. Biochem. Pharmacol 42, 963–972 (1991).
   PubMed Web of Science ®Google Scholar
• Cihlar T, Chen MS. Identification ofenzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mal Pharmacol 50, 1502–1510 (1996).
   PubMed Web of Science ®Google Scholar
• Balzarini J, Nave J-F, Becker MA, Tatibana M, De Clercq E.Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coil, rat liver and human erythrocytes. Nucleosides Nucleotides 14,1861–1871 (1995).
   Google Scholar
• Merta A, Votruba I, Jindrich J, et al Phosphorylation of 9-(2-phosphonomethoxyethyl)-adenine by AMP (dAMP) kinase from L1210. Biochem. Pharmacol 44, 2067–2077 (1992).
   PubMed Web of Science ®Google Scholar
• Neyts J, Snoeck R, Balzarini J, De Clercq E. Particular characteristics of the antihuman cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropy1)-cytosine (HE'MPC) in vitm. Antiviral Res. 16,41–52 (1991).
   PubMed Web of Science ®Google Scholar
• Ho H-T, Woods KL, Bronson JJ, De Boeck, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyll-cytosine. Mal Pharmacol 41,197–202 (1992).
   PubMed Web of Science ®Google Scholar
• Aldern KA, Ciesla SL, Winegarden KL,Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovirin MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.Mol. Pharmacol. 63, 678–681 (2003).
   Google Scholar
• Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.Antimicrob. Agents Chemother. 46, 991–995 (2002).
   PubMed Web of Science ®Google Scholar
• Beadle JR, Hartline C, Aldern KA, etal. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother 46, 2381–2386 (2002).
   Google Scholar
• Kramata P, Votruba I, Otové. B, Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases a, X and E. Mol. Pharmacol 49,1005–1011 (1996).
   PubMed Web of Science ®Google Scholar
• Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8,1–23 (1997).
   Web of Science ®Google Scholar
• Birkus G, Hijek M, Kramata P, Votruba I, Holy A, Otové. B. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases a, 8 and E. Antimicrob. Agents Chemother 46,1610–1613 (2002).
   PubMed Web of Science ®Google Scholar
• Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41,594–599 (1997).
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oiled Res. 10,523–531 (1998).
   Google Scholar
• Murono S, Raab-Traub N, Pagano JS. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res. 61,7875–7877 (2001).
   PubMed Web of Science ®Google Scholar
• Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. The antiviral agent cidofovir ([51-1-[3-hydroxy-2-phosphonyl-methoxypropylicytosine) has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 58, 384–388 (1998).
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol. Res. 12,397–408 (2001).
   Web of Science ®Google Scholar
• Abdulkarim B, Sabri S, Deutsch E, etal. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21, 2334–2346 (2002).
   PubMed Web of Science ®Google Scholar
• De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med. Vim!. 3,85–96(1993).
   Web of Science ®Google Scholar
• Neyts J, De Clercq E. In vitro and in vivo inhibition of murine gamma herpes virus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother 42,170–172 (1998).
   PubMed Web of Science ®Google Scholar
• Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. j Clin. Invest. 99,2082–2086 (1997).
   Google Scholar
• Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. Characterization of wild type and cidofovir-resistant strains of camelpox, cowpox, monkeypox and vaccinia viruses. Antimicrob. Agents Chemother. 46,1329–1335 (2002).
   PubMed Web of Science ®Google Scholar
• Nettleton PF, Gilray JA, Reid HW, Mercer AA. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 48, 205–208 (2000).
   PubMed Web of Science ®Google Scholar
• De Clercq E. Cidofovir in the treatment of poxvirus infections. Anti vim! Res. 55,1–13 (2002).
   PubMed Web of Science ®Google Scholar
• •Timely review of the potential usefulness of cidofovir in the therapy and short-term prophylaxis of poxvirus infections, including smallpox (variola) and complications of smallpox vaccinations (vaccinia).
   Google Scholar
• De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Wands Pharmacol Sci. 23, 456–458 (2002).
   PubMed Web of Science ®Google Scholar
• •Timely review of the potential usefulness of cidofovir in the therapy and short-term prophylaxis of poxvirus infections, including smallpox (variola) and complications of smallpox vaccinations (vaccinia).
   Google Scholar
• De Clercq E, Naesens L, De Bolle L, Schots D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Merl Vim]: 11, 381–395 (2001).
   Google Scholar
• Smee DF, Burger RA, Warren RP, Bailey KW, Sidwell RW. An immunosuppressed mouse model of lethal murine gammaherpesvirus 68 infection for studying potential treatment of Epstein-Barr virus infection in man. Antiviral Chem. Chemother. 8,573–581 (1997).
   Web of Science ®Google Scholar
• Christensen ND, Pickel MD, Budgeon LR, Kreider RV. In 141,0 antipapillomavirus activity of nucleoside analogues including cidofovir on CRP V-inducedrabbit papillomas. Antiviral Res. 48,131–142 (2002).
   Google Scholar
• Duan J, Paris W, De Marte J, Roopchand D, Fleet T-L, Cordingley MG. Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence. Anti vim! Res. 46,135–144 (2000).
   PubMed Web of Science ®Google Scholar
• Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropy1)-cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. j Med. Virol 41,242–246 (1993).
   PubMed Web of Science ®Google Scholar
• •First demonstration of efficacy of cidofovir in the treatment of a poxvirus infection (i.e. vaccinia) in an imrnunocompromised host.
   Google Scholar
• Smee DF, Bailey KW, Wong M-H, Sidwell RVV. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52,55–62 (2001).
   PubMed Web of Science ®Google Scholar
• Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181,10–19 (2000).
   PubMed Web of Science ®Google Scholar
• Bray M, Martinez M, Kefauver D, West M, Roy R. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Anti vim! Res. 54,129–142 (2002).
   PubMed Web of Science ®Google Scholar
• Smee DF, Bailey KW, Wong M-H, Sidwell RW. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Anti vim! Res. 47,171–177 (2001).
   Web of Science ®Google Scholar
• Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Inhibitory effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic-nude mice. Oncol. Res. 10, 533–539 (1998).
   PubMed Web of Science ®Google Scholar
• Liekens S, Andrei G, Vandeputte M, De Clercq E, Neyts J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. CancerRes. 58,2562–2567 (1998).
   Web of Science ®Google Scholar
• Liekens S, Verbeken E, De Clercq E, Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int. Cancer92, 161–167 (2001)
   Google Scholar
• Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res. 61, 5057–5064 (2001).
   PubMed Web of Science ®Google Scholar
• Redondo P, Idoate M, Galofré JC, Solano T Cidofovir inhibits growth of B16 melanoma cells in vivo. BE j Dermatol.143,741–748 (2002).
   Web of Science ®Google Scholar
• Cullen JM, Li DH, Brown C, etal Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 45, 2740–2745 (2001).
   PubMed Web of Science ®Google Scholar
• Julander JG, Sidwell RW, Money JD. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 55, 27–40 (2002).
   PubMed Web of Science ®Google Scholar
• Delmas J, Schorr O, Jamard C, et al Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in Om and in sdtra Antimiavb. Agents Chemother 46, 425–433 (2002).
   PubMed Web of Science ®Google Scholar
• Tsai C-C, Follis KE, Sabo A, et al Prevention of SW infection in macaques by (R)-9-(2-phosphonylmethoxypropyOadenine. Science270, 1197–1199 (1995).
   PubMed Web of Science ®Google Scholar
• ••First report demonstrating the efficacy oftenofovir in the post-exposure prophylaxis of an immunodeficiency virus infection.
   Google Scholar
• Tsai C-C, Fouls KE, Beck TVV, Sabo A, Bischofberger N, Dailey PJ. Effects of (R)-9-(2-phosphonylmethoxypropyOadenine monotherapy on chronic SW infection in macaques. AIDS Res. Hum. Retroviruses 13, 707–712 (1997).
   PubMed Web of Science ®Google Scholar
• Van Rompay KKA, McChesney MB, Aguirre NL, Schmidt IKA, Bischofberger N, Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. Infect. Dis. 184, 429–438 (2001).
   Web of Science ®Google Scholar
• Often RA, Smith DK, Adams DR, etal.Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus Type 2). J. Vim!. 74, 9771–9775 (2000).
   Google Scholar
• Lalezari JP, Stagg RJ, Kuppermann BD, et al Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann. Intern Med. 126, 257–263 (1997).
   PubMed Web of Science ®Google Scholar
• •Clinical study that provided the basis for the formal licensing of cidofovir in the treatment of cytomegalovirus retinitis in AIDS patients.
   Google Scholar
• Studies of Ocular Complications of AIDSResearch Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann. Intern. Med. 126, 264–274 (1997).
   PubMed Web of Science ®Google Scholar
• •Clinical study that provided the basis for the formal licensing of cidofovir in the treatment of cytomegalovirus retinitis in AIDS patients.
   Google Scholar
• Lacy SA, Hitchcock MJ, Lee WA, Tellier P,Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sri. 44, 97–106 (1998)
   PubMed Web of Science ®Google Scholar
• Cihlar T, Lin DC, Pritchard JB, Fuller MD,Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mal Pharmacol 56, 570–580 (1999).
   PubMed Web of Science ®Google Scholar
• The Studies of Ocular Complications ofAIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC peripheral cytomegalovirus retinitis trial. AIDS14, 1571–1581 (2000).
   Google Scholar
• Lalezari JP, Holland GN, Kramer F, etal Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. I Acquir. Immune Dellc. Syndrom. Human Retrovirol 17, 339–344 (1998).
   Web of Science ®Google Scholar
• The Studies of Ocular Complications of AIDSResearch Group in Collaboration with the AIDS Clinical Trials Group. The ganciclovir implant plus oral gancidovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the gancidovir cidofovir cytomegalovirus retinitis trial. Am Ophthalmol 131, 457–467 (2001).
   PubMed Web of Science ®Google Scholar
• •Corroborates the efficacy of cidofovir in the treatment of cytomegalovirus retinitis in AIDS patients [49,50].
   Google Scholar
• Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127–143 (1999).
   PubMed Web of Science ®Google Scholar
• Polis MA, Spooner KM, Baird BF, etal.Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimiavb. Agents Chemother. 39, 882–886 (1995).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Bandt D, Thiede C, etal.Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 71, 880–885 (2001).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Deliliers GL, Platzbecker U, etal Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. B/ooc/97, 388–392 (2001).
   Google Scholar
• Kopp T, Geusau A, Rieger A, Stingl G.Successful treatment of an aciclovir-resistant herpes simplex Type 2 infection with cidofovir in an AIDS patient. BE Dermatol 147, 134–138 (2002).
   PubMed Web of Science ®Google Scholar
• Lalezari J, Schacker T, Feinberg J, etal. A randomized, double-blinded, placebo-controlled trial of cidofovir gel for the treatment of acyclovir unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. j Infect. Dis. 176, 892–898 (1997).
   Web of Science ®Google Scholar
• Sacks SL., Shafran SD, Diaz-Mitoma F, etal A multicenter Phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimiavb. Agents Chemother. 42, 2996–2999 (1998).
   PubMed Web of Science ®Google Scholar
• Blot N, Schneider P, Young P, et al Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone MarIVW Transplant. 26, 903–905 (2000).
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Drew WL, Glutzer E, etal (5)-1-[3-Hydroxy-2-(phosphonylmethoxy)-propylicytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. j Infect. Dis. 171, 788–796 (1995).
   Web of Science ®Google Scholar
• Hanel M, Fiedler F, Thorns C. AntiCD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 24, 491–494 (2001).
   PubMed Web of Science ®Google Scholar
• Meerbach A, Schacke M, Hyckel P, Kosmehl H, Wutzler P Successful treatment of Epstein-Barr virus-associated tumors in a heart transplant patient with cidofovir. Case report. Abstracts 15th International Conference on Antiviral Research, Prague, Czech Republic, 17–21 March 2002. Antiviral Res. 53 (2002) (Abstract 62, no 91).
   Google Scholar
• Mazzi R, Parisi SG, Sarmati L, etal Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS15, 2061-2063 (2001).
   Google Scholar
• Fife K, Gill J, Bourboulia D, Gazzard B, Nelson M, Bower M. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. BE I Dermatol 141, 1136–1153 (1999).
   PubMed Web of Science ®Google Scholar
• Simonart T, Noel J-C, De Dobbeleer G, etal Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. I Med. Viral 55, 215–218 (1988).
   Google Scholar
• Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin. Infect. Dis. 28, 690–691 (1999).
   PubMed Web of Science ®Google Scholar
• Legrand F, Berrebi D, Houhou N, etal Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrowtransplantation in children. Bone Marrow Transplant. 27, 621–626 (2001).
   PubMed Web of Science ®Google Scholar
• Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biology of Blood and Marrow. 71ansplantation 7, 388–394 (2001)
   Google Scholar
• De Luca A, Giancola ML, Ammassari A, etal Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS14, F117-F121 (2000).
   Google Scholar
• •One of the more extensive clinical studies pointing to the efficacy of cidofovir in the treatment of progressive multifocal leukoencephalopathy (PML).
   Google Scholar
• Brambella AM, Castagna A, Novati R, et al Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J. Neural. 246, 723–725 (1999).
   PubMed Web of Science ®Google Scholar
• De Luca A, Fantoni M, Tartaglione T,Antinori A. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 52, 891–892 (1999).
   Google Scholar
• Portilla J, Boix V, Roman F, Reus S, Merino E. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active antiretroviral therapy. J. Infect. 41, 182–184 (2000).
   Google Scholar
• Razonable RR, Aksamit AJ, Wright AJ, Wilson JW. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin. Proc. 76, 1171–1175 (2001).
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Stingele K, Hartmann M, Haas J, von Einsiedel R, Wildemann B. Succesful treatment of AIDS related PML with HAART and cidofovir. Eur j Merl Res. 6, 190–192 (2001).
   PubMed Web of Science ®Google Scholar
• Vats A, Shapiro R, Randhawa PS, et al Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75, 105–112 (2003).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Snoeck R, Van Ranst M, etal Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S) 1 (3 hydroxy-2-phosphonylmethoxypropy0cytosine. Med. Vim]. 45, 230–235 (1995).
   Google Scholar
• ••Spectacular regression of large hypopharyngeal/esophagal papillomatous lesions following topical injections of cidofovir.
   Google Scholar
• Snoeck R, Van Ranst M, Andrei G, Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl. J. Med. 333, 943–944 (1995).
   PubMed Web of Science ®Google Scholar
• Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm. Infect. 76, 143–152 (2000).
   PubMed Web of Science ®Google Scholar
• Scharmann D, Bergmann F, Temmesfield-Wollbrack B, Grobusch MP, Suttorp N. Topical cidofovir is effective in treating extensive penile condylomata acuminata. 4IDS14, 1075-1076 (2000)..
   Google Scholar
• Matteelli A, Beltrame A, Graifemberghi S, etal Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm. Dis. 28, 343–346 (2001).
   PubMed Web of Science ®Google Scholar
• Snoeck R, Bossens M, Parent D, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33, 597–602 (2001).
   PubMed Web of Science ®Google Scholar
• •Only double-blind study that has proven the efficacy of cidofovir in the (local) treatment (as a topical gel) of papillomatous lesions.
   Google Scholar
• Orlando G, Fasolo MM, Beretta R, MerliS, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS16, 447–450 (2002).
   Google Scholar
• Snoeck R, Noël JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CINJ. Merl Vim'.60, 205–209 (2000).
   Google Scholar
• Koonsaeng S, Verschraegen C, Freedman R, etal Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. Med. Vim]. 64, 195–198 (2001).
   Google Scholar
• Snoeck R, Wellens W, Desloovere C, etal Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(5)-1-(3-hydroxy-2-phosphonylmethoxypropy1)-cytosine, HPMPC]. J. Med Viral 54, 219–225 (1998).
   PubMed Web of Science ®Google Scholar
• Bielamowicz S, Villagomez V, Stager SV, Wilson WR. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 112, 696–699 (2002).
   PubMed Web of Science ®Google Scholar
• Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg 125, 1143–1148 (1999).
   Web of Science ®Google Scholar
• Stragier I, Snoeck R, De Clercq E, Van den Oord JJ, Van Ranst M, De Greef H. Local treatment of HPV-induced skin lesions by cidofovir. j Merl Viral. 67, 241–245 (2002).
   PubMed Web of Science ®Google Scholar
• Bienvenu B, Martinez F, Devergie A, et al Topical use of cidofovir induced acute renal failure. 71ansplantation 73, 661–662 (2002).
   Google Scholar
• Meadows IQ, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol 133, 987–990 (1997).
   PubMedGoogle Scholar
• Ibarra V, Blanco JR, Oteo JA, Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm. Venereal. 80, 315–316 (2000).
   Google Scholar
• Geerinck K, Lukito G, Snoeck R, etal A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Merl Viral. 64, 543–549 (2001).
   Google Scholar
• ••Spectacular regression of giant orf(ecthyma) lesion following local (cream) treatment with cidofovir.
   Google Scholar
• Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. J. Am. Med. Assoc. 282, 2305–2312 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher EJ, Chaloner K, Cohn DL, etal The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 15, 1695–1700 (2001).
   PubMed Web of Science ®Google Scholar
• Gilson RJ, Chopra KB, Newell AM, etal A placebo-controlled Phase VII study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 6, 387–395 (1999).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V, etal Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358, 718–723 (2001).
   PubMed Web of Science ®Google Scholar
• •Successful treatment with adefovir dipivoxil of chronic, lamivudine-resistant, hepatitis B virus infections.
   Google Scholar
• Benhamou Y, Bochet M, Thibault V, et al Adefovir dipivoxil 10 mg suppresses HBV viral replication in HIV/HBV co-infected patients with lamivudine resistant HBV. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington USA, 24–28 February (2002).
   Google Scholar
• Peters M, Hann HW, Martin P, etal Adefovir dipivoxil alone and in combination with lamivudine suppresses lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. Abstracts 37th Annual Meeting of the European Association for the Study of Liver Diseases, Madrid, Spain, 17–21 April (2002).
   Google Scholar
• Marcellin P, Chang T-T, Lim SG, et al Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl. J Med. 348,808–816 (2003).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive study pertaining to thesuccessful treatment of chronic hepatitis B with adefovir dipivoxil, as monitored by different laboratory (histological, virological and biochemical) parameters.
   Google Scholar
• Perrillo R, Schiff E, Yoshida E, et al Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32,129–134 (2000).
   PubMed Web of Science ®Google Scholar
• Peters MG, Singer G, Howard T, etal. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient. Transplantation 68,1912–1914 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 49, 436–440 (2001).
   PubMed Web of Science ®Google Scholar
• Mutimer D, Feraz-Neto BH, Harrison R, et al Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 49, 860–863 (2001).
   PubMed Web of Science ®Google Scholar
• Mutimer D. Adefovir dipivoxil for the treatment of chronic hepatitis B. Abstracts Therapies for Viral Hepatitis, Boston, MA, USA, 29–31 October 2002. Antiviral Ther. 7, L84, no. 6 (2002).
   Google Scholar
• Mutimer D, Hann H-WL, Buti M, et al Safety and efficacy of adding adefovir dipivoxil to lamivudine in decompensated patients with YMDD variant and a reduced response to lamivudine — one year results. Abstracts Therapies for Viral Hepatitis, Boston, MA, USA, 29–31 October 2002. Antiviral Ther. 7, L90, no. 16 (2002).
   Google Scholar
• Bendele RA, Richardson FC. Adefovir nephrotoxicity and mitochondrial DNA depletion. Human Pathol 33,574 (2002).
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barditch-Crovo P, Lietman PS, etal Safety, pharmacokinetics and antiretroviral activity of intravenous 942-(R)-phosphonomethoxy)propylladenine, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother 42, 2380–2384 (1998).
   PubMed Web of Science ®Google Scholar
• Schooley RT, Ruane P, Myers RA, etal. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS16, 1257–1263 (2002).
   Google Scholar
• •Double-blind, placebo-controlled study showing HIV-1 load reduction with tenofovir disoproxil fumarate over a 48-week period.
   Google Scholar
• Squires K, Pierone G, Berger D, etal Tenofovir DF: a 48-week final analysis from a Phase III randomized, double-blind placebo-controlled study in antiretroviral experienced patients. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA USA, 24–28 February (2002).
   Google Scholar
• Staszewski S, Gallant J, Pozniak A, etal Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. Abstracts XIV International AIDS Conference, Barcelona, Spain, 7–12 July (2002).
   Google Scholar
• Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 54, 37–45 (2002).
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJM, Cihlar T Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46,716–723 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson AA, Ray AS, Hanes J, et al Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. j Biol. Chem. 276, 40847–40857 (2001).
   Web of Science ®Google Scholar
• Cooper D, Cheng A, Coakley D, et al AntiHBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV co-infected. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 24–28 February (2002).
   Google Scholar
• Bochet M, Tubiana R, Benhamou Y, et al Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients co-infected with HIV/HBV. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 24–28 February (2002).
   Google Scholar
• Cherrington JM. Human cytomegalovirus: resistance profile of cidofovir. Int. Antiviral News5, 91–92 (1997).
   Google Scholar
• Scharmann D, Bergmann F, Grobusch MP, Behnsch M, Liekfeld A. Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir. AIDS12, 678–679 (1998).
   Google Scholar
• Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology248, 382–393 (1998).
   Google Scholar
• Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P, Opdenakker G. Resistance of herpes simplex virus Type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene.J Gen. Viral. 81,639–648 (2000).
   PubMed Web of Science ®Google Scholar
• Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus Type 1 reverse transcriptase confers decreased susceptibility to 9-(2-phosphonomethoxyethyl) adenine in vitro. Antimicrob. Agents Chemother. 40, 2212–2216 (1996).
   Google Scholar
• Miller MD, Margot NA, Lamy PD, et al Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. Acquir Immune Dellc. Synclr. 27,450–458 (2001).
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Marcelin A-G, Thibault V, etal Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coninfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother. 46,1586–1588 (2002).
   PubMed Web of Science ®Google Scholar
• Chin R, Shaw T, Torresi J, etal In vitro susceptibilities of wild type or drug-resistant hepatitis B virus to ( ) D 2,6 diaminopurine dioxolane and 2'-fluoro-5-methyl-3-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45, 2495–2501 (2001).
   PubMed Web of Science ®Google Scholar
• Tatti KM, Korba BE, Stang HL, et al Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res. 55, 141–150 (2002).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, etal Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl Med. 348,800–807 (2003).
   PubMed Web of Science ®Google Scholar
• ••Adefovir dipivoxil is effective in thetreatment of both HBeAg-positive chronic hepatitis B (ref. 103) and HBeAg-negative chronic hepatitis B (this reference). Unlike larnivudine, adefovir dipivoxil does not lead to apparent resistance development.
   Google Scholar
• Benhamou Y, Bochet M, Thibault V, et al Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. Abstracts 37th Annual Meeting of the European Association for the Study of Liver Diseases, Madrid, Spain, 17–21 April (2002).
   Google Scholar
• Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethykarbonyOPMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42, 1484–1487 (1998).
   PubMed Web of Science ®Google Scholar
• Van Rompay KKA, Miller MD, Marthas ML, etal. Prophylactic and therapeutic benefits of short-term 9-(2-[R1-[phosphonomethoxy] propyl)-adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. j Viral. 74,1767–1774 (2000).
   PubMed Web of Science ®Google Scholar
• Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus Type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46,2179–2184 (2002).
   PubMed Web of Science ®Google Scholar
• Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DE AIDS 16,1227–1235 (2002).
   PubMed Web of Science ®Google Scholar
• Margot NA, Johnson A, Cheng A, Coakley DF, Miller MD. Final 48-week genotypic and phenotypic analyses of study 907: tenofovir DF (TDF) added to stable background regimens. Abstracts 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington USA, 24–28 February (2002).
   Google Scholar
• Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus Type 1 isolates. Ant/in/crab. Agents Chemother. 46, 1067–1072 (2002).
   PubMed Web of Science ®Google Scholar